News | Peripheral Artery Disease (PAD) | November 09, 2018

iDissection Classification Study to Evaluate Dissection Rate of Flex Dynamic Scoring Catheter

New study to determine if Flex Catheter reduces dissections and the need for bailout stents in peripheral arteries

iDissection Classification Study to Evaluate Dissection Rate of Flex Dynamic Scoring Catheter

November 9, 2018 — VentureMed Group Inc. announced the initiation of a new study to determine if the Flex Dynamic Scoring Catheter reduces dissections and the need for bailout stents in peripheral arteries. The study, entitled “Arterial Dissections Following FLEX Scoring and Adjunctive Balloon Angioplasty: Intravascular Ultrasound Assessment and Correlation with Angiographic Findings,” will utilize intravascular ultrasound (IVUS) to identify the health of the vessel after treatment.

Nicolas W. Shammas, M.D., founder and director of the Midwest Cardiovascular Research Foundation in Davenport, Iowa is the principal investigator for the study. This study is the second iDissection study performed by Shammas. The first study revealed that after atherectomy, in the peripheral arteries, significant dissections are more visible by a ratio of 6:1 when using IVUS in comparison to the typical angiogram. Deducing that the presence and severity of dissection after atherectomy may have been underestimated, especially for deeper dissections which are associated with recurrent restenosis, recoil and possibly acute closure.

“After the indicative results of the initial iDissection study, I am motivated to look for vessel prep devices that further reduce the need for provisional stenting,” said Shammas. “I am optimistic about the ability of the Flex Catheter to reduce the rate of high-grade dissections and looking forward to the evaluation.”

Using IVUS, the new study will evaluate the dissection rates of 15 patients following treatment of femoropopliteal denovo or no-stent restenosis by the Flex Dynamic Scoring Catheter and plain old balloon angioplasty (POBA).

VentureMed Group was an exhibitor at Vascular Interventional Advances (VIVA) in Las Vegas and the VEITH Symposium in New York during the month of November.

For more information: www.venturemedgroup.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now